98 results
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
12 Mar 24
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
4:10pm
European Union (EU) marketing authorization, as we do not plan to commercially launch ZYNRELEF in the U.K. or the EU.
Please see full prescribing
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
24 Jan 24
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
8:01am
2023, we cancelled the ZYNRELEF European Union (EU) marketing authorization, as we do not plan to commercially launch ZYNRELEF in the U.K. or the EU
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
11 Jan 24
Entry into a Material Definitive Agreement
4:07pm
the ZYNRELEF European Union (EU) marketing authorization, as we do not plan to commercially launch ZYNRELEF in the U.K. or the EU.
About Heron Therapeutics
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
14 Nov 23
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
4:10pm
. In August 2023, we cancelled the ZYNRELEF U.K. marketing authorization and, in October 2023, we cancelled the ZYNRELEF European Union (EU) marketing
424B3
ezctz4k8j 3928a
5 Sep 23
Prospectus supplement
9:14pm
8-K
EX-99.1
5q8u1eg28 rjgpbg7c
14 Aug 23
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
4:11pm
8-K
EX-10.1
wxuw6awgyq jldwemht
24 Jul 23
Heron Therapeutics Announces $30 Million Private Placement Financing
9:12am
8-K
EX-99.1
0fnqfvu vvbwgh
8 Nov 22
Results of Operations and Financial Condition
4:10pm
424B5
rlypuvd n1mi0dtiifv5
20 Oct 22
Prospectus supplement for primary offering
4:06pm
8-K
EX-10.1
rzam bsmzyp0y4
10 Aug 22
Entry into a Material Definitive Agreement
4:46pm